X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (142) 142
rituximab (84) 84
oncology (79) 79
index medicus (70) 70
male (65) 65
female (62) 62
middle aged (62) 62
adult (54) 54
aged (53) 53
hematology (49) 49
antineoplastic agents - therapeutic use (43) 43
non-hodgkins-lymphoma (37) 37
treatment outcome (36) 36
antibodies, monoclonal - therapeutic use (33) 33
b-cell lymphoma (31) 31
antibodies, monoclonal, murine-derived (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
follicular lymphoma (29) 29
prognosis (29) 29
lymphoma, non-hodgkin - drug therapy (27) 27
anti-cd20 monoclonal-antibody (26) 26
cancer (26) 26
aged, 80 and over (23) 23
animals (23) 23
chemotherapy (23) 23
chronic lymphocytic-leukemia (22) 22
antibodies, monoclonal - administration & dosage (20) 20
survival (20) 20
lymphoma (19) 19
lymphoma, non-hodgkin - therapy (19) 19
antineoplastic agents - pharmacology (18) 18
cell line, tumor (18) 18
disease-free survival (18) 18
lymphomas (18) 18
therapy (18) 18
care and treatment (17) 17
chop chemotherapy (17) 17
hemic and lymphatic diseases (17) 17
antibodies, monoclonal - adverse effects (16) 16
antineoplastic agents - adverse effects (16) 16
low-grade (16) 16
mice (16) 16
transplantation (16) 16
abridged index medicus (15) 15
article (15) 15
lymphoma, b-cell - drug therapy (15) 15
lymphoma, follicular - drug therapy (15) 15
lymphoma, large b-cell, diffuse - drug therapy (15) 15
thalidomide - analogs & derivatives (15) 15
antibodies, monoclonal, murine-derived - administration & dosage (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
lymphoma, non-hodgkin - pathology (14) 14
neoplasm staging (14) 14
non-hodgkin's lymphoma (14) 14
survival rate (14) 14
antineoplastic agents - administration & dosage (13) 13
clinical trials as topic (13) 13
diffuse large b-cell lymphoma (13) 13
doxorubicin - administration & dosage (13) 13
drug resistance, neoplasm (13) 13
recurrence (13) 13
survival analysis (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
bortezomib (12) 12
immune system diseases (12) 12
leukemia, lymphocytic, chronic, b-cell - drug therapy (12) 12
mice, scid (12) 12
non-hodgkin lymphoma (12) 12
combined modality therapy (11) 11
diagnosis (11) 11
lymphoma, large b-cell, diffuse - pathology (11) 11
lymphoma, non-hodgkin - immunology (11) 11
non-hodgkin's lymphomas (11) 11
risk factors (11) 11
young adult (11) 11
analysis (10) 10
apoptosis - drug effects (10) 10
chronic lymphocytic leukemia (10) 10
expression (10) 10
follow-up studies (10) 10
immunology (10) 10
lenalidomide (10) 10
lymphoma, b-cell - metabolism (10) 10
lymphoma, b-cell - therapy (10) 10
lymphoma, follicular - mortality (10) 10
monoclonal antibodies (10) 10
multicenter (10) 10
radioimmunotherapy (10) 10
thalidomide - therapeutic use (10) 10
antibodies, monoclonal - immunology (9) 9
antibodies, monoclonal - pharmacology (9) 9
antibodies, monoclonal, humanized (9) 9
antigens, cd20 - immunology (9) 9
apoptosis (9) 9
cd20 (9) 9
cyclophosphamide - administration & dosage (9) 9
elderly-patients (9) 9
immunohistochemistry (9) 9
lymphoma, b-cell - pathology (9) 9
multiple-myeloma (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 12/2013, Volume 11 Suppl 19, Issue 12, p. 8
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 12, pp. 1149 - 1159
Journal Article
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 2015, pp. e449 - e457
Personalized therapy for the treatment of patients with cancer is rapidly approaching and is an achievable goal in the near future. A substantial number of... 
Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Gene Expression Profiling | Lymphoma, Large B-Cell, Diffuse - genetics | Precision Medicine - methods
Journal Article
Journal Article
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 08/2012, Volume 10, Issue 8, pp. 8 - 9
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 01/2017, Volume 58, Issue 1, pp. 62 - 62
In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demonstrated an overall response rate of 82% among 45 patients with relapsed or refractory... 
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 01/2017, Volume 58, Issue 1, p. 62
  In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demonstrated an overall response rate of 82% among 45 patients with relapsed or... 
Nuclear medicine | Medical treatment | Clinical trials | Lymphomas | Comparative analysis
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 01/2017, Volume 58, Issue 1, pp. 62 - 68
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2008, Volume 140, Issue 1, pp. 36 - 45
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2006, pp. 303 - 310
Follicular lymphoma (FL) is the most common subtype of indolent lymphoma. Specific "facts" about FL that were generated by past research and have been passed... 
Lymphoma, Follicular - mortality | Palliative Care | Lymphoma, Follicular - therapy | Dissent and Disputes | Humans | Practice Guidelines as Topic
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2085 - 2093
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3997 - 3997
Abstract Background: Results from the Collaborative trial in relapsed aggressive lymphoma (CORAL) study highlighted the poor clinical outcome of... 
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 12/2013, Volume 9, Issue 12, pp. 1829 - 1839
Ofatumumab is a fully human, IgG anti-CD20 monoclonal antibody codeveloped by GlaxoSmithKline (Brentford, UK) and Genmab (Copenhagen, Denmark). In preclinical... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.